Research Article| Volume 306, ISSUE 1-2, P173-179, July 15, 2011

Insight into the mechanism of laquinimod action

  • W. Brück
    Corresponding author at: Institut für Neuropathologie, Universitätsmedizin Göttingen, Georg-August-Universität, Robert-Koch-Str. 40, 37075 Göttingen, Germany. Tel.: +49 551 3922700; fax: +49 551 3910800.
    Department of Neuropathology, University Medical Center, Georg-August University, Göttingen, Germany
    Search for articles by this author
  • C. Wegner
    Department of Neuropathology, University Medical Center, Georg-August University, Göttingen, Germany
    Search for articles by this author
Published:March 23, 2011DOI:


      Laquinimod is a small, novel, orally active, well-tolerated molecule that significantly reduced gadolinium-enhancing lesions in patients with multiple sclerosis (MS). Orally administered laquinimod was found to be present within the central nervous system (CNS) in both healthy mice and mice with experimental autoimmune encephalomyelitis (EAE). Laquinimod inhibits development of both acute and chronic EAE. Furthermore, laquinimod minimizes inflammation, demyelination and axonal damage in MOG-induced EAE in mice treated at disease induction and following clinical disease onset. In vitro, laquinimod down-regulates secretion of pro-inflammatory cytokines and enhances production of anti-inflammatory cytokines from peripheral blood mononuclear cells (PBMCs) derived from healthy subjects and untreated relapsing remitting (RR) MS patients. Additionally, patients treated with laquinimod demonstrate up-regulation of brain-derived neurotrophic factor (BDNF) in the serum. In conclusion, treatment with laquinimod is effective in reducing inflammation, demyelination and axonal damage.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Comi G.
        • Pulizzi A.
        • Rovaris M.
        • Abramsky O.
        • Arbizu T.
        • Boiko A.
        • et al.
        Effect of laquinimod on MRI-monitored disease activity in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
        Lancet. 2008; 371: 2085-2092
        • Steinman L.
        Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.
        Cell. 1996; 85: 299-302
        • Prat A.
        • Antel J.
        Pathogenesis of multiple sclerosis.
        Curr Opin Neurol. 2005; 18: 225-230
        • Sospedra M.
        • Martin R.
        Immunology of multiple sclerosis.
        Annu Rev Immunol. 2005; 23: 683-747
        • Brunmark C.
        • Runström A.
        • Ohlsson L.
        • Sparre B.
        • Brodin T.
        • Astrom M.
        • et al.
        The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
        J Neuroimmunol. 2002; 130: 163-172
        • Zou L.P.
        • Abbas N.
        • Volkmann I.
        • Nennesmo I.
        • Levi M.
        • Wahren B.
        • et al.
        Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue.
        Neuropharmacol. 2002; 42: 731-739
      1. (AB 0330045)
        Distribution of radioactivity after administration of 14C-ABR-215062 to a EAE-diseased mice. Pilot studies.
        in: Active biotech research study report. June 2005
      2. (BMD-07-03-5600)
        In vitro effect of TV-5600 on healthy human PMBCs proliferation, viability and cytokine/chemokine secretion.
        BMD, TEVA R&D, March 2010
      3. (AA32235)
        Laquinimod sodium: 4 week oral (gavage) immunotoxicity study in the Sprague Dawley rat.
        MDS Pharma Services, FranceSeptember 2007 (Final Report)
      4. (HeartTx/Teva-LQ/Jun06)
        Laquinimod does not result in prolongation of heart survival in a model of allogeneic heterotopic rat heart transplants.
        Teva Pharmaceutical Industries, IsraelJuly 2006 (Final Report)
        • Wegner C.
        • Stadelmann C.
        • Pförtner R.
        • Raymond E.
        • Feigelson S.
        • Alon R.
        • et al.
        Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
        J Neuroimmunol. 2010; 227: 133-143
        • Yu M.
        • Nishiyama A.
        • Trapp B.D.
        • Tuohy V.K.
        Interferon-beta inhibits progression of relapsing–remitting experimental autoimmune encephalomyelitis.
        J Neuroimmunol. 1996; 64: 91-100
        • Tuohy V.K.
        • Yu M.
        • Yin L.
        • Mathisen P.M.
        • Johnson J.M.
        • Kawczak J.A.
        Modulation of the IL-10/IL-12 cytokine circuit by interferon-ß inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis.
        J Neuroimmunol. 2000; 111: 55-63
        • Yasuda C.L.
        • Al-Sabbagh A.
        • Oliveira E.C.
        • Diaz-Bardales B.M.
        • Garcia A.A.
        • Santos L.M.B.
        Interferon-ß modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion.
        Immunol Invest. 1999; 28: 115-126
        • Luca M.E.
        • Visser L.
        • Lucas C.J.
        • Nagelkerken L.
        IFN-ß modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in SJL mouse.
        J Neuroimmunol. 1999; 100: 190-196
        • Runstrom A.
        • Leanderson T.
        • Ohlsson L.
        • Axelsson B.
        Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-ß k.o. and wild type mice.
        J Neuroimmunol. 2006; 173: 69-78
        • Wujek J.R.
        • Bjartmar C.
        • Richer E.
        • Ransohoff R.M.
        • Yu M.
        • Tuohy V.K.
        • et al.
        Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.
        J Neuropathol Exp Neurol. 2002; 61: 23-32
        • Wegner C.
        • Stadelmann C.
        • Kaye J.
        • Fine T.
        • Mayk A.
        • Raymond E.
        • et al.
        Mult Scler. 2007; 13 (P836): S7-S273
        • Sättler M.B.
        • Togni M.
        • Gadjanski I.
        • Sühs K.W.
        • Meyer N.
        • Bähr M.
        • et al.
        Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis.
        J Neuroimmunol. 2008; 193: 77-86
        • Sühs K.W.
        • Diem R.
        Effects of laquinimod on axon degeneration in autoimmune optic neuritis.
        Mult Scler. 2007; 13 (P835): S7-S273
        • Yang J.S.
        • Xu L.Y.
        • Xiao B.G.
        • van der Meide P.H.
        • Hedlund G.
        • Link H.
        Laquinimod (ABR-215062) suppresses the development of experimental and autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-ß in Lewis rats.
        J Neuroimmunol. 2004; 156: 3-9
        • Achiron A.
        • Timan B.
        • Kaye J.
        • Hayardeny L.
        Laquinimod reduces level of IL17 in cultured splenocytes from treated MOG induced experimental autoimmune encephalomyelitis and in cultured PBMCs from healthy human donors.
        Neurology. 2008; 70 (P07.127)
        • Linker R.
        • Thöne J.
        • Comi G.
        • Gold R.
        Laquinimod induces up-regulation of neurotrophins in serum of patients with relapsing–remitting multiple sclerosis.
        Mult Scler. 2009; 15 (P783): S151-S269